Patents by Inventor Franck Sandrinelli

Franck Sandrinelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds with anti-tumoral activity
    Patent number: 10570122
    Abstract: The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 25, 2020
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Oxazole derivatives that inhibit Syk
    Patent number: 10392373
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 27, 2019
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Claire Schalon, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK
    Publication number: 20190055230
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 21, 2019
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Claire Schalon, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Benzimidazole derivatives as selective proteine kinase inhibitors
    Patent number: 10202370
    Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 12, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Abdellah Benjahad, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Jason Martin, Willy Picoul
  • Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
    Patent number: 10053455
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: August 21, 2018
    Assignee: AB SCIENCE
    Inventors: Abdellah Benjahad, Jason Martin, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Willy Picoul, Alain Moussy
  • DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS
    Publication number: 20180179195
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.
    Type: Application
    Filed: March 23, 2015
    Publication date: June 28, 2018
    Inventors: Abdellah BENJAHAD, Jason MARTIN, Claire SCHALON, Didier PEZ, Emmanuel CHEVENIER, Franck SANDRINELLI, Willy PICOUL, Alain MOUSSY
  • COMPOUNDS WITH ANTI-TUMORAL ACTIVITY
    Publication number: 20180079747
    Abstract: The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description.
    Type: Application
    Filed: February 5, 2016
    Publication date: March 22, 2018
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS
    Publication number: 20160152608
    Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 2, 2016
    Inventors: Alain MOUSSY, Abdellah BENJAHAD, Claire SCHALON, Didier PEZ, Emmanuel CHEVENIER, Franck SANDRINELLI, Jason MARTIN, Willy PICOUL
  • Selective protein kinase inhibitors
    Patent number: 9168245
    Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: October 27, 2015
    Assignee: AB SCIENCE
    Inventors: Abdellah Benjahad, Alain Moussy, Emmanuel Chevenier, Willy Picoul, Anne Lermet, Didier Pez, Jason Martin, Franck Sandrinelli
  • Thiazole and oxazole kinase inhibitors
    Patent number: 8962665
    Abstract: The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: February 24, 2015
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Jason Martin, Emmanuel Chevenier, Didier Pez, Franck Sandrinelli, Willy Picoul
  • SELECTIVE PROTEIN KINASE INHIBITORS
    Publication number: 20140179698
    Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Application
    Filed: July 24, 2012
    Publication date: June 26, 2014
    Applicant: AB SCIENCE
    Inventors: Abdellah Benjahad, Alain Moussy, Emmanuel Chevenier, Willy Picoul, Anne Lermet, Didier Pez, Jason Martin, Franck Sandrinelli
  • THIAZOLE AND OXAZOLE KINASE INHIBITORS
    Publication number: 20130035331
    Abstract: The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.
    Type: Application
    Filed: January 12, 2011
    Publication date: February 7, 2013
    Applicant: AB SCIENCE
    Inventors: Alain Moussy, Abdellah Benjahad, Jason Martin, Emmanuel Chevenier, Didier Pez, Franck Sandrinelli, Willy Picoul